tiprankstipranks
Trending News
More News >
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
US Market

Akebia Therapeutics (AKBA) Technical Analysis

Compare
1,405 Followers

Technical Sentiment

Overall Consensus
Buy
15Bullish
2Neutral
5Bearish
Technical Analysis Consensus
Sell
3Bullish
2Neutral
5Bearish
Moving Average Consensus
Strong Buy
12Bullish
0Neutral
0Bearish
Akebia Therapeutics’s (AKBA) Moving Averages Convergence Divergence (MACD) indicator is 0.02, suggesting Akebia Therapeutics is a Sell.
Akebia Therapeutics’s (AKBA) 20-Day exponential moving average is 1.94, while Akebia Therapeutics’s (AKBA) share price is $2.16, making it a Buy.
Akebia Therapeutics’s (AKBA) 50-Day exponential moving average is 1.95, while Akebia Therapeutics’s (AKBA) share price is $2.16, making it a Buy.

Akebia Therapeutics (AKBA) Pivot Points

Apr 24, 2025, 12:36 PM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
1.99
2.03
2.08
2.12
2.17
2.21
2.26
Fibonacci
2.03
2.06
2.08
2.12
2.15
2.17
2.21
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Akebia Therapeutics (AKBA) Moving Averages

Apr 24, 2025, 12:36 PM
Period
Simple
Exponential
MA5
2.07Buy
2.07Buy
MA10
1.89Buy
1.98Buy
MA20
1.88Buy
1.94Buy
MA50
1.96Buy
1.95Buy
MA100
1.99Buy
1.91Buy
MA200
1.73Buy
1.69Buy
Akebia Therapeutics’s (AKBA) 10-Day exponential moving average is 1.98, while Akebia Therapeutics’s (AKBA) share price is $2.16, making it a Buy.
Akebia Therapeutics’s (AKBA) 100-Day exponential moving average is 1.91, while Akebia Therapeutics’s (AKBA) share price is $2.16, making it a Buy.
Akebia Therapeutics’s (AKBA) stock price is $2.16 and Akebia Therapeutics’s (AKBA) 50-day simple moving average is 1.96, creating a Buy signal.
Akebia Therapeutics’s (AKBA) stock price is $2.16 and Akebia Therapeutics’s (AKBA) 100-day simple moving average is 1.99, creating a Buy signal.
Akebia Therapeutics’s (AKBA) stock price is $2.16 and Akebia Therapeutics’s (AKBA) 200-day simple moving average is 1.73, creating a Buy signal.

Akebia Therapeutics (AKBA) Technical Indicators

Apr 24, 2025, 12:36 PM
Name
Value
Implied Action
RSI (14)
60.20
Neutral
STOCH (9,6)
89.38
Sell
STOCHRSI (14)
89.38
Sell
MACD (12,26)
0.02
Sell
ADX (14)
14.68
Buy
Williams %R
-14.67
Sell
CCI (14)
173.84
Sell
ATR (14)
0.16
-
Ultimate Oscillator
58.62
Neutral
ROC
11.92
Buy
Akebia Therapeutics’s (AKBA) Relative Strength Index (RSI) is 60.20, creating a Neutral signal.
Akebia Therapeutics’s (AKBA) Trend Strength Indicator (ADX) is 14.68, creating a Buy signal.
Akebia Therapeutics’s (AKBA) Commodity Channel Index (CCI) is 173.84, creating a Sell signal.
Akebia Therapeutics’s (AKBA) Price Rate of Change (ROC) is 11.92, creating a Buy signal.

FAQ

Is AKBA a Buy, Hold, or Sell?
Based on AKBA’s technical indicators, AKBA is a Buy.
    What is AKBA’s RSI (14)?
    AKBA’s RSI (14) is 60.20, which suggests AKBA is a Neutral.
      What is AKBA’s MACD?
      AKBA’s MACD is 0.02, which suggests AKBA is a Sell.
        What is AKBA’s 5-day moving average?
        AKBA’s 5-day moving average is 2.07, which suggests AKBA is a Buy.
          What is AKBA’s 20-day moving average?
          AKBA 20-day moving average is 1.88, which suggests AKBA is a Buy.
            What is AKBA’s 50-day moving average?
            AKBA’s 50-day moving average is 1.96, which suggests AKBA is a Buy.
              What is AKBA’s 200-day moving average?
              AKBA’s 200-day moving average is 1.73, which suggests AKBA is a Buy.
                What is AKBA’s Williams % R (14)?
                AKBA’s Williams % R (14) is -14.67, which suggests AKBA is a Sell.
                  What is AKBA’s CCI (14)?
                  AKBA’s CCI (14) is 173.84, which suggests AKBA is a Sell.
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis